Results 201 to 210 of about 387,352 (250)
Some of the next articles are maybe not open access.
Advancements in Biologic Therapy for Psoriasis: the IL-23 Inhibitors
Current Dermatology Reports, 2021The purpose of this article is to review clinical trials evaluating the efficacy and safety of IL-23 inhibitors in the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis. Guselkumab, tildrakizumab, and risankizumab have been approved for the treatment of psoriasis. Mirikizumab is still under investigation in phase 3 studies. IL-23
Edward Hadeler +5 more
openaire +1 more source
IL-23 Inhibitors for Psoriasis
Current Dermatology Reports, 2018The purpose of this article is to review current understanding of the role of IL-23 in psoriasis and the available results to date on clinical trials establishing the efficacy and safety of IL-23 inhibitors for use in adults with moderate-to-severe plaque psoriasis.
Kristen M. Beck +3 more
openaire +1 more source
IL-23 inhibitors for moderate-to-severe psoriasis
Seminars in Cutaneous Medicine and Surgery, 2018Since the identification of high levels of interleukin 23 (IL- 23) in psoriasis lesional skin, as well as finding that IL-23 was the most important source of the p40 subunit shared by IL-12 and IL-23, significant effort has been made in identifying potential new drugs that specifically block the unique IL-23 p19 subunit.
Erin, Ibler, Kenneth B, Gordon
openaire +2 more sources
Anti‐drug antibodies of IL‐23 inhibitors for psoriasis: a systematic review
Journal of the European Academy of Dermatology and Venereology, 2022AbstractAnti‐drug antibodies (ADAs) can form with certain biological medications, but their clinical significance is not fully understood. ADA formation in psoriasis patients treated with IL‐23 inhibitors was evaluated, looking at the incidence of ADAs, impact on clinical outcomes and association with adverse events.
Norden, A +5 more
openaire +3 more sources
Interleukin (IL)-12/23 and IL-23 Inhibitors
2022Biologic therapies have transformed the treatment of moderate-to-severe psoriasis. This is a rapidly evolving field, with several new monoclonal antibody medications reaching the market over the last few years. A number of classes of biologic agents now exist, corresponding to the underlying cytokine target of the antibody therapy. The interleukin (IL)-
Earnshaw, Charles, Warren, Richard B.
openaire +2 more sources
Differentiating IL-23 Inhibitors in Crohn’s Disease
DrugsInterleukin-23 (IL-23), a member of the IL-12 family of cytokines, plays a critical role in intestinal homeostasis and inflammation and is strongly implicated in the pathogenesis of inflammatory bowel disease (IBD). Therapies targeting the p19 subunit of IL-23 have recently expanded the therapeutic options for IBD demonstrating efficacy and safety for ...
Olga Maria Nardone +4 more
openaire +3 more sources
Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults
Expert Review of Clinical Immunology, 2020Guselkumab is a subcutaneously administered human monoclonal antibody, selectively blocking IL-23 through binding to its p19 subunit. It was initially approved for the treatment of patients with moderate-to-severe plaque-psoriasis who are candidates for systemic therapy or phototherapy.
Boehncke, Wolf-Henning +2 more
openaire +5 more sources
Dermatologic Therapy, 2017
The rapid progress of genetic engineering furthermore opens up new prospects in the therapy of this difficult-to-treat disease. IL-23 inhibitors, phosphodiesterase 4 (PDE4) inhibitors, and Janus kinase (JAK) inhibitors are currently encouraging further research. Two drugs which are IL-23 inhibitors are now in phase III of clinical trials.
Dominika Wcisło-Dziadecka +4 more
openaire +3 more sources
The rapid progress of genetic engineering furthermore opens up new prospects in the therapy of this difficult-to-treat disease. IL-23 inhibitors, phosphodiesterase 4 (PDE4) inhibitors, and Janus kinase (JAK) inhibitors are currently encouraging further research. Two drugs which are IL-23 inhibitors are now in phase III of clinical trials.
Dominika Wcisło-Dziadecka +4 more
openaire +3 more sources
Risankizumab: IL-23 inhibitor u liječenju psorijaze
Medix (Zagreb), 2020The IL-23 / Th17 axis is a central development in the immunopathogenesis of psoriasis. Risankizumab (Skyrizi) is indicated for the treatment of moderate to severe plaque psoriasis in adults. Risankizumab is a humanized high-affinity IgG1 monoclonal antibody for the p19 subunit of IL-23, thus preventing IL-23 from binding to the receptor over an ...
openaire +2 more sources
New Kids on the Block: IL-23 Inhibitors in IBD Management
Current Gastroenterology ReportsReview the efficacy and safety of IL2319 inhibitors in the management of IBD.Risankizumab, mirikizumab, and guselkumab have been found to be efficacious and safe in the management of IBD. IL23p19 inhibitors have been found to be successful in the management of IBD.
Jacob, Jones +4 more
openaire +2 more sources